MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Hutchmed to get payment from Takeda as Fruzaqla launched in Japan

ALN

Hutchmed (China) Ltd on Friday said it will receive a milestone payment from Takeda Pharmaceutical Co Ltd after Takeda launched Hutchmed’s Fruzaqla in Japan.

Hutchmed is a Hong Kong-based biopharmaceutical maker focused on the treatment of cancer and immunological disease, and develops and markets Fruzaqla, whose generic name is fruquintinib, in China.

Takeda is a Tokyo-based pharmaceutical company with the exclusive worldwide licence to develop, commercialise and manufacture fruquintinib outside of mainland China.

The launch of Fruzaqla is for patients with previously treated metastatic colorectal cancer, following approval by the Japanese Ministry of Health, Labour & Welfare.

Hutchmed did not on Friday provide the amount of the milestone payment that it will receive. In October, it had said it received a $20 million payment as Takeda had delivered $203 million in net sales of Fruzaqla in first nine months of 2024.

Hutchmed shares were flat at 281.00 pence each on Friday morning in London, while Takeda shares closed 0.2% lower at JP¥4,113.00 each in Tokyo.

Copyright 2024 Alliance News Ltd. All Rights Reserved.